2. UroToday Home
  3. Video Lectures

mCRPC Treatment Videos

Debate: PARP Inhibitors for All mCRPC Patients APCCC 2022 Presentation - Noel Clarke
September 15, 2022
Details
Risk-Adapted Treatment Monitoring in mCRPC APCCC 2022 Presentation - Anwar Padhani
September 14, 2022
Details
Is There Still a Role for Radium-223? APCCC 2022 Presentation - Neal Shore
September 14, 2022
Details
How To Read a Genomic Testing Report APCCC 2022 Presentation - Kim Chi
September 1, 2022
Details
Optimal Treatment Sequencing in mCRPC APCCC 2022 Presentation - Maha Hussain
August 29, 2022
Details
Treating Metastatic Castration-Resistant Prostate Cancer Session Discussion APCCC 2022 Presentation - Silke Gillessen
August 25, 2022
Details
Debate: PARP Inhibitors Only in Selected mCRPC Patients APCCC 2022 Presentation - Johann de Bono
August 18, 2022
Details
The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo
June 19, 2022
Details
Symptomatic and Health Related Quality of Life Benefits With Olaparib in Men With mCRPC Carrying Mutations in the Homologous Recombination Repair Genes, Journal Club - Christopher Wallis & Zachary Klaassen
May 24, 2022
Details
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
April 14, 2022
Details
Significant Improvement With Continuous Enzalutamide in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer – Axel Merseburger
March 25, 2022
Details
The Risk of Prostate Cancer in Men with Inherited Germline TP53 Variants - Kara Maxwell
March 16, 2022
Details
Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor
December 26, 2021
Details
CheckMate 9KD Trial CohortA2 Evaluating Nivolumab + Rucaparib for Chemotherapy-Naïve mCRPC - Daniel Petrylak
November 7, 2021
Details
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi
September 19, 2021
Details
The Efficacy of Olaparib in the PROfound Study – Fred Saad
September 12, 2021
Details
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff
August 12, 2021
Details
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
August 12, 2021
Details
Assessing Concordance in DDR Gene Alterations Between Primary Prostate Cancer and Metastases or ctDNA – Bruce Montgomery
August 10, 2021
Details
COncurrent adMinistration of Bipolar Androgen Therapy and nivolumab in men with mCRPC, The COMBAT Study - Mark Markowski
July 29, 2021
Details
Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit
May 5, 2021
Details
TRANSFORMER - A Study Comparing Bipolar Androgen Therapy Vs Enzalutamide in mCRPC - Emmanuel Antonarakis
April 30, 2021
Details
Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal
January 29, 2021
Details
NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff
January 18, 2021
Details
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans
January 7, 2021
Details
Improving Quality Imaging in Prostate Cancer with Gallium 68 PSMA-11 - Johannes Czernin
January 7, 2021
Details
Discussing the Efficacy and Safety from Results of the Dose Escalation Arm of AMG 160, a Bispecific T-Cell Engager (BiTE) Immune Therapy Targeting PSMA for Metastatic Castration-Resistant Prostate Cancer - Ben Tran, Oliver Sartor, and Neal Shore
November 30, 2020
Details
Preliminary Efficacy of AMG 160 in Metastatic Castration-Resistant Prostate Cancer, Interim Results From the Phase 1 Study - Tanya Dorff
November 16, 2020
Details
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer - Karim Fizazi
October 26, 2020
Details
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran
October 5, 2020
Details
Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans
September 29, 2020
Details
PROfound: Olaparib for Metastatic Castrate Resistant Prostate Cancer - Thomas Keane
July 2, 2020
Details
Effect of Cabazitaxel vs Abiraterone or Enzalutamide on Patient-Reported Outcomes in mCRPC: A Pre-Planned EQ-5D-5L Analysis of the CARD Study - Neal Shore
June 27, 2020
Details
Cabazitaxel Demonstrates Improved Overall Survival when Compared to an Alternative AR-targeted Agent (CARD) - Cora Sternberg
June 21, 2020
Details
The Clinical Implications of The Efficacy and Safety in Older Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone or Enzalutamide In The CARD Trial - William Oh and Stephen Freedland
June 7, 2020
Details
Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida
June 3, 2020
Details
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Sweeney
June 2, 2020
Details
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer - Rahul Aggarwal
May 16, 2020
Details
FDA Approves First PARP Inhibitor Rucaparib for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Charles Ryan
May 15, 2020
Details
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor
May 7, 2020
Details
Optimal Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Evan Yu
May 5, 2020
Details
The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran
April 7, 2020
Details
The Clinical Implications and Health-related Quality of Life Benefits: Reviewing the CARD Study Results in Men with mCRPC - Neal Shore
February 23, 2020
Details
CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi
February 17, 2020
Details
Optimal Steroid Use with Abiraterone - Gerhardt (Gert) Attard
January 6, 2020
Details
RET Signaling in Neuroendocrine Prostate Cancer - Justin Drake
January 6, 2020
Details
Radiation Oncology Studies: Changing the Course of Disease for Men with Metastatic Prostate Cancer - Phuoc Tran
January 21, 2020
Details
Bone Health Agents in Patients with Castrate-Resistant Prostate Cancer - Bertrand Tombal
January 16, 2020
Details
Antibody-drug Conjugates for Metastatic Urothelial Carcinoma & 177Lu-PSMA-617 for Progressive mCRPC - Scott Tagawa
November 25, 2019
Details
Clinical Implications of the CARD Trial - Cora Sternberg
November 17, 2019
Details
New Therapeutic Targets for Metastatic Castration-Resistant Prostate Cancer - Aaron LeBeau
November 8, 2019
Details
The Current State of Cell-free DNA in Prostate Cancer - Alexander Wyatt
January 14, 2020
Details
Immunotherapy and Personalized Medicine in Prostate Cancer - Akash Patnaik
November 13, 2019
Details
Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer - Bertrand Tombal
October 17, 2019
Details
Immunotherapy in Metastatic Prostate Cancer - Charles Drake
February 2, 2020
Details
Personalized Medicine in Prostate Cancer - Arpit Rao
January 24, 2020
Details
Management of Castration-Resistant Prostate Cancer - Cora Sternberg
October 7, 2019
Details
Guiding First Line Treatment Decisions for mCRPC After ADT + Docetaxel or AR Pathway Inhibitor - Mary-Ellen Taplin
September 26, 2019
Details
Local Treatment of the Primary Tumor (Radiotherapy) in the Metastatic Setting - Robert Bristow
September 25, 2019
Details
Oligometastatic Prostate Cancer – Definitions and Concepts Presentation - Robert Reiter
September 18, 2019
Details
PARP Inhibition for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presentation - Kim Chi
September 18, 2019
Details
Treatment of Oligometastatic and Oligoprogressive CRPC Presentation - Eric Small
September 18, 2019
Details
Oligorecurrent Prostate Cancer Presentation - Piet Ost
September 18, 2019
Details
De-Novo Oligometastatic Disease: Consensus and Controversy on Aims, Options, and Rationale Presentation - Michael J. Morris
September 18, 2019
Details
Immunotherapy for Metastatic Castration Resistant Prostate Cancer Presentation - Charles Drake
September 17, 2019
Details
Results and Lessons Learned from the Consensus Conference for Developing Countries - Fernando Maluf
February 2, 2020
Details
Clinical Trial Treatment Options for Rare GU Malignancies - Bradley McGregor
September 12, 2019
Details
Local Treatment of the Primary Tumor (Surgery) in the Metastatic Setting Presentation - Thomas Steuber
September 5, 2019
Details
Report and Lessons Learned From The Consensus Conference For Developing Countries Presentation - Fernando Maluf
September 4, 2019
Details
DKK1 and Prostate Cancer - David Wise
August 1, 2019
Details
A Prognostic Model for Overall Survival in Men with Metastatic Castration-resistant Prostate Cancer - Susan Halabi
August 11, 2019
Details
Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients – Oliver Sartor
August 1, 2019
Details
Radium-223 in Clinical Practice - Phillip J. Koo
August 2, 2019
Details
Management of mCRPC using Sipuleucel-T - Evan Yu
June 22, 2019
Details
Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal
June 11, 2019
Details
Contemporary Sequencing in the Treatment of Prostate Cancer - Neal Shore, Alicia Morgans and Charles Ryan
May 31, 2019
Details
The Changing Therapeutic Landscape of Prostate Cancer- Nicholas Vogelzang
May 12, 2019
Details
Improved Survival Outcomes of African America Men with mCRPC Treated with Sipuleucel-T - Kelvin Moses
April 23, 2019
Details
Treatment Decisions for Patients with Metastatic Castration-resistant Prostate Cancer: A Retrospective Study of Real-World Experience - Tia Higano
March 27, 2019
Details
Racial Disparities in Prostate Cancer Treatment and Outcomes - Susan Halabi
February 12, 2019
Details
Improving Natural Killer Cell Immunotherapy for Cancer - Martin Felices
February 6, 2019
Details
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer - Oliver Sartor
February 5, 2019
Details
The Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade - Wassim Abida
January 31, 2019
Details
Targeting Glutamine Metabolism Pathways for the Treatment of Prostate Cancer - Richard Lee
January 30, 2019
Details
Introducing TIN 117m for Convention Electron Therapy of mCRPC - Suresh Srivastava
January 28, 2019
Details
PROPHECY Trial: Circulating Tumor Cell as a Biomarker in mCRPC - Andrew Armstrong
December 5, 2018
Details
The Process of Metastasis in Prostate Cancer - Kenneth Pienta
November 18, 2018
Details
An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.
October 28, 2018
Details
Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad
October 11, 2018
Details
Prospective Study of Low-Dose Abiraterone with Food Versus Standard Dose Abiraterone in mCRPC - Russell Szmulewitz
May 8, 2018
Details
Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad
May 3, 2018
Details
UPWARD Study - Seizure Rates in Enzalutamide-Treated Men with mCRPC - Susan Slovin
January 6, 2018
Details
email news signup